Follow
Disha Gandhi
Disha Gandhi
Neurocrine Biosciences
No verified email - Homepage
Title
Cited by
Cited by
Year
Monitoring Replication Protein A (RPA) dynamics in homologous recombination through site-specific incorporation of non-canonical amino acids
N Pokhrel, S Origanti, EP Davenport, D Gandhi, K Kaniecki, RA Mehl, ...
Nucleic acids research 45 (16), 9413-9426, 2017
552017
Characterization of Protease-Activated Receptor (PAR) ligands: Parmodulins are reversible allosteric inhibitors of PAR1-driven calcium mobilization in endothelial cells
DM Gandhi, MW Majewski, R Rosas Jr, K Kentala, TJ Foster, E Greve, ...
Bioorganic & medicinal chemistry 26 (9), 2514-2529, 2018
242018
Synthetic analogues of the snail toxin 6-bromo-2-mercaptotryptamine dimer (BrMT) reveal that lipid bilayer perturbation does not underlie its modulation of voltage-gated …
C Dockendorff, DM Gandhi, IH Kimball, KS Eum, R Rusinova, ...
Biochemistry 57 (18), 2733-2743, 2018
232018
Discovery, Optimization, and Characterization of ML417: A Novel and Highly Selective D3 Dopamine Receptor Agonist
AE Moritz, RB Free, WS Weiner, EO Akano, D Gandhi, A Abramyan, ...
Journal of medicinal chemistry 63 (10), 5526-5567, 2020
192020
Design and evaluation of heterobivalent PAR1–PAR2 ligands as antagonists of calcium mobilization
MW Majewski, DM Gandhi, R Rosas Jr, R Kodali, LA Arnold, ...
ACS medicinal chemistry letters 10 (1), 121-126, 2018
192018
The parmodulin NRD-21 is an allosteric inhibitor of PAR1 Gq signaling with improved anti-inflammatory activity and stability
DM Gandhi, R Rosas Jr, E Greve, K Kentala, DRD N'Guessan, VA Snyder, ...
Bioorganic & medicinal chemistry 27 (17), 3788-3796, 2019
112019
Synthesis and initial pharmacology of dualtargeting ligands for putative complexes of integrin αVβ3 and PAR2
HWCD Mark W. Majewski, Disha M. Gandhi, Trudy Holyst, Zhengli Wang, Irene ...
RSC Med. Chem, 940-949, 2020
32020
NMR Structural analysis of isolated Shaker voltage-sensing domain in LPPG micelles
H Chen, J Pan, DM Gandhi, C Dockendorff, Q Cui, B Chanda, ...
Biophysical Journal 117 (2), 388-398, 2019
32019
Synthesis and Initial Pharmacology of Heterobivalent Ligands Targeting Putative Complexes of Integrin αVβ3 and PAR2
M Majewski, D Gandhi, T Holyst, Z Wang, I Hernandez, R Rosas Jr, ...
12019
D3 dopamine receptor-selective negative allosteric modulators
D Gandhi, K Frankowski, M Ferrer, RB Free, DR Sibley, AE Moritz, ...
US Patent App. 18/294,663, 2024
2024
Discovery, Characterization, and Optimization of a Novel Positive Allosteric Modulator-Antagonist of the D3 Dopamine Receptor
KK Snyder, AE Moritz, N Madaras, F Wang, A Kelley, D Gandhi, E Akano, ...
Journal of Pharmacology and Experimental Therapeutics 389 (S3), 2024
2024
Structure–Activity Relationships of a Brain-Penetrant D3 Dopamine Receptor Negative Allosteric Modulator and Investigation of its Binding Site
AE Moritz, NS Madaras, LR Inbody, AM Kelley, DM Gandhi, EO Akano, ...
Journal of Pharmacology and Experimental Therapeutics 385 (S3), 2023
2023
Heterocyclic ligands of PAR1 and methods of use
C Dockendorff, DM Gandhi, R Rosas
US Patent 11,130,743, 2021
2021
Heterocyclic ligands of par1 and methods of use
C DOCKENDORFF, DM GANDHI, JR ROSAS
2020
Structure‐Activity Relationships of a Negative Allosteric Modulator of the D3 Dopamine Receptor and Investigation of its Binding Site
AE Moritz, LR Inbody, DM Gandhi, E Akano, C Fearce, RB Free, ...
The FASEB Journal 34 (S1), 1-1, 2020
2020
Strategies for the Modulation of Protease Activated Receptors (PARs)
DM Gandhi
2018
Lipid Bilayer Perturbation by the Snail Toxin 6-Bromo-2-Mercaptotryptamine Dimer does not Account for its Modulation of Voltage-Gated Potassium Channels
C Dockendorff, D Gandhi, I Kimball, KS Eum, R Rusinova, H Ingólfsson, ...
Biophysical Journal 112 (3), 246a-247a, 2017
2017
Supporting Information Design and Evaluation of Heterobivalent PAR1–PAR2 Ligands as Antagonists of Calcium Mobilization.
MW Majewski, DM Gandhi, R Rosas Jr, C Dockendorff
The system can't perform the operation now. Try again later.
Articles 1–18